4/29/2010

Roche Holding said European regulators approved Tarceva as a maintenance treatment for advanced nonsmall-cell lung cancer. The drug received FDA approval earlier this month for this indication. Roche also said its Type 2 diabetes treatment taspoglutide yielded positive results in a late-stage trial.

Full Story:
Reuters

Related Summaries